Deferasirox is indicated for the treatment of chronic iron overload due to frequentblood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with betathalassemia major aged 6 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload due to bloodtransfusions when deferoxamine therapy is contraindicated or inadequate in the followingpatient groups:
-in pediatric patients with beta thalassemia major with iron overload due tofrequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
Deferasirox is indicated for the treatment of chronic iron overload due to frequentblood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with betathalassemia major aged 6 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload due to bloodtransfusions when deferoxamine therapy is contraindicated or inadequate in the followingpatient groups:
-in pediatric patients with beta thalassemia major with iron overload due tofrequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
Aminocaproic acid is indicated for use in patients of all ages in haemorrhage caused by local or general fibrinolysis, including in Postsurgical haemorrhages in:
•Urology (surgery of the bladder and prostate)
•Gynaecology (cervical surgery), in patients where tranexamic acid is not available or not tolerated
•Obstetrics (post-partum and post-miscarriage haemorrhages) after correction of the coagulation defect
•Heart surgery (with or without bypass placement)
•Gastroenterology
•Odonto-stomatology (dental extractions in haemophiliacs, patients undergoing anticoagulanttherapy) Life-threatening haemorrhages induced by thrombolytics (streptokinase, etc.). Haemorrhages associated with thrombocytopenia, thrombopenic purpura, leukaemia. Nonsurgical haematuria of the lower urinary tract (secondary to cystitis, etc.). Intense menstruations, menorrhagia and haemorrhagic metropathies. Angioneurotic oedema.
Schizophrenia and other psychoses (especially paranoia), mania and hypomania. In anxiety, psychomotor agitation, excitement, violent or dangerously impulsive behavior. Is used as an adjunct in the short-term management of these conditions.
·Intractable hiccup.
·Nausea and vomiting in terminal illness (where other drugs have failed or are not available).
·Induction of hypothermia is facilitated by Chlorpromazine Tablets which prevents shivering and causes vasodilatation.
Childhood schizophrenia and autism
Chlorpromazine Hydrochloride is intended for the following indications:
treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
Chlorpromazine Hydrochloride is intended for the following indications:
treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
SITFORT is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
SITFORT is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
SITFORT is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.
SITFORT is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control
SITFORT is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
SITFORT is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
SITFORT is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist.
SITFORT is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control
Ovarian cancer
Olaparib BOS is indicated as monotherapy for the:
• maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2- mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first line platinum-based chemotherapy.
• maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Olaparib BOS in combination with bevacizumab is indicated for the:
• maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
Breast cancer
Olaparib BOS is indicated as:
• monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germlineBRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
• monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxanein the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
Adenocarcinoma of the pancreas
Olaparib BOS is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutationswho have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Prostate cancer
Olaparib BOS is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included anew hormonal agent.
